WARREN, N.J., Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of pediatric and adult patients living with phenylketonuria (PKU). A Prescription Drug User Fee Act (PDUFA) target action date is expected to be provided in the Day 74 Letter. "The FDA filing acceptance for sepiapterin is a critical milestone toward bringing this potential important therapy to children and adults livi ...

Collaboration to Drive PTC's Onshape Initiatives Including Discovery Program, Onshape AI Advisor, and CAD and PDM Conversion Tools BOSTON, Sept. 25, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced entry into a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to accelerate the growth of its Onshape® cloud-native computer-aided design (CAD) and product data management (PDM) solution. This collaboration will focus on advancing Onshape product enhancements, customer adoption program ...

SolStock PTC Therapeutics, Inc. (NASDAQ:PTCT) continues to make significant progress in its pipeline. This is especially true when you consider that it has already been able to report positive interim results from its phase 2 PIVOT-HD study, which used PTC518 for the treatment of patients with Huntington's Disease [HD]. The last time I wrote about this article in a Seeking Alpha article entitled "PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts," data for PTC518 was not released. Not o ...

Core Insights - PTC has appointed Rob Bernshteyn to its Board of Directors, effective September 9, 2024 [1][2] - Bernshteyn has over 30 years of experience in the enterprise software industry, including 14 years as CEO and Chairman of Coupa Software, where he led a successful IPO in 2016 [2] - He will serve on the Compensation & People Committee of the PTC Board [3] Company Overview - PTC is a global software company that facilitates digital transformation for industrial and manufacturing companies, focusing on the design, manufacturing, and servicing of physical products [3] - The company is headquartered in Boston, Massachusetts, employs over 7,000 people, and supports more than 30,000 customers worldwide [3]

It has been about a month since the last earnings report for PTC Inc. (PTC) . Shares have added about 0.7% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is PTC Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. PTC's Q3 Earnings Meet Estimates PTC reported third ...

WARREN, N.J., Aug. 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Thursday, Sept. 5 at 9:15 am ET 2024 Wells Fargo Healthcare Conference Friday, Sept. 6 at 12:00 pm ET Cantor 2024 Global Healthcare Conference Tuesday, Sept. 17 at 2:30 pm ET The presentations will be webcast live on the Events and Presentations page under the Investor section o ...

BOSTON, Aug. 27, 2024 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences. What: Citi's 2024 Global TMT Conference When: Wednesday, September 4th, 2024 at 8:20am ET What: 2024 RBCCM Global TIMT Conference When: Tuesday, November 19th, 2024 What: Barclays 22nd Annual Global Technology Conference When: Wednesday, December 11th, 2024 What: Nasdaq 51st Investor Conference When: Wednesday, December 11th, 2024 To view the webcast and replay for conferences pleas ...

This industrial software company continues to grow its key metric and cash flow. Industrial software stock PTC (PTC 1.60%) is the sort of company investors should consider buying into on a dip. The company's recent third-quarter results, for the period ended June 30, and commentary on its fiscal 2025 were impressive in the current environment, and this company's long-term growth is only starting. Here's why PTC is a great stock for long-term holders. Attractive end markets PTC's software solutions help cust ...

– Continued strong revenue performance – – NDAs for sepiapterin and Translarna™ submitted to FDA – – Positive interim data readout from PTC518 PIVOT-HD study – – On track to achieve remaining 2024 clinical and regulatory milestones – WARREN, N.J., Aug. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2024. "I am proud of our team's continued outstanding execution as we have accomplished all our obje ...

Q3'24 FINANCIAL RESULTS Neil Barua CEO Kristian Talvitie CFO July 31, 2024 FORWARD LOOKING STATEMENTS 2 This presentation includes forward looking statements regarding PTC's future financial performance, strategic outlook and expectations, anticipated future operations, and expected effects of strategic investments and initiatives. Because such statements deal with future events, actual results may differ materially from those projected in the forwardlooking statements. Information about factors that could ...